Shares of BioDelivery Sciences International Inc. (NASDAQ:BDSI) traded up 5.5% on Wednesday . The stock traded as high as $2.55 and last traded at $2.48, with a volume of 328,252 shares traded. The stock had previously closed at $2.35.

Several analysts have recently weighed in on the company. Cantor Fitzgerald reissued a “hold” rating on shares of BioDelivery Sciences International in a report on Saturday, July 9th. Piper Jaffray Cos. reissued an “overweight” rating and set a $4.00 price objective (down previously from $6.00) on shares of BioDelivery Sciences International in a report on Thursday, May 12th. FBR & Co lifted their price objective on BioDelivery Sciences International from $9.00 to $12.00 and gave the stock an “outperform” rating in a report on Wednesday, May 4th. Zacks Investment Research raised BioDelivery Sciences International from a “hold” rating to a “buy” rating and set a $3.00 price objective on the stock in a report on Thursday, July 14th. Finally, Roth Capital reaffirmed a “buy” rating on shares of BioDelivery Sciences International in a research note on Monday, March 28th. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $8.25.

The company has a 50-day moving average price of $2.47 and a 200-day moving average price of $3.14. The firm’s market cap is $128.63 million.

BioDelivery Sciences International (NASDAQ:BDSI) last released its quarterly earnings data on Tuesday, May 10th. The specialty pharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by $0.01. The business earned $3 million during the quarter, compared to analysts’ expectations of $2.96 million. During the same quarter last year, the company earned ($0.16) EPS. The firm’s revenue for the quarter was down 77.1% on a year-over-year basis. On average, equities research analysts expect that BioDelivery Sciences International Inc. will post ($1.19) EPS for the current year.

Other hedge funds have added to or reduced their stakes in the company. 1492 Capital Management LLC raised its stake in BioDelivery Sciences International by 8.3% in the fourth quarter. 1492 Capital Management LLC now owns 538,538 shares of the specialty pharmaceutical company’s stock valued at $2,580,000 after buying an additional 41,069 shares in the last quarter. Turner Investments L.P. raised its position in shares of BioDelivery Sciences International by 55.4% in the fourth quarter. Turner Investments L.P. now owns 900,830 shares of the specialty pharmaceutical company’s stock worth $4,315,000 after buying an additional 321,290 shares during the period. Royce & Associates LLC raised its position in shares of BioDelivery Sciences International by 6.2% in the fourth quarter. Royce & Associates LLC now owns 1,487,800 shares of the specialty pharmaceutical company’s stock worth $7,127,000 after buying an additional 87,200 shares during the period. Bank of Montreal Can raised its position in shares of BioDelivery Sciences International by 3.6% in the fourth quarter. Bank of Montreal Can now owns 829,056 shares of the specialty pharmaceutical company’s stock worth $3,971,000 after buying an additional 28,838 shares during the period. Finally, Sei Investments Co. raised its position in shares of BioDelivery Sciences International by 240.1% in the fourth quarter. Sei Investments Co. now owns 330,789 shares of the specialty pharmaceutical company’s stock worth $1,584,000 after buying an additional 233,519 shares during the period.

BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.